Ascentage Pharma Group InternationalvsAbbVie

AAPG and ABBV stock compared: price, dividend, valuation and results, from SEC filings.

AAPG

Ascentage Pharma Group International

$11.97

Value $1.1B

-3.78%
AAPG's page

Ascentage Pharma Group International (AAPG) has a market value of $1.1B and AbbVie (ABBV) $506B. Over the last year, with dividends, AAPG moved -62.8% and ABBV +26.6%. Dividend yield: AAPG none, ABBV 2.42%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AAPG$1.1B

    ABBV$506B

    ABBV is 453 times AAPG

  • Revenue, 12 months

    AAPG$82M

    ABBV$66.0B

    ABBV is 804 times AAPG

  • Net income, 12 months

    AAPG-$178M

    ABBV$10.3B

  • Operating margin

    AAPG-215.3%

    ABBV32.2%

    247.5 points apart

  • ROIC

    AAPG-73.2%

    ABBV25.7%

    98.9 points apart

  • P/E

    AAPG–

    ABBV49.2

  • Dividend yield

    AAPG0.0%

    ABBV2.4%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AAPG-62.8%

ABBV+26.6%

50100DecFebAprJunAugOct
Returns by period
PeriodAAPGWith dividendsABBVWith dividends
1 year since November 19, 2025-62.8%Price -62.8%+26.6%Price +22.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AAPGAscentage Pharma Group InternationalABBVAbbVie

Valuation

AAPGABBV
Valuation
Price$11.97$286.20
Market value$1.1B$506B
Enterprise value (EV)$946M$576B
P/E–49.2
P/E, 5-year median–57.0
P/B5.9–
EV/EBIT–27.1
Free cash flow yield–3.7%

Results and growth

AAPGABBV
Results and growth
Revenue, 12 months$82M$66.0B
Net income, 12 months-$178M$10.3B
Free cash flow, 12 months-$172M$18.9B
Earnings per share, 12 months-$2.00$5.81
Revenue growth, year on year-41.5%8.6%
Revenue growth a year, past+39.9%over 3 years+5.9%over 5 years
EPS growth a year, past–-2.8%over 5 years

Margins and returns on capital

AAPGABBV
Margins and returns on capital
Gross margin91.5%73.7%
Operating margin-215.3%32.2%
Net margin-216.5%15.7%
ROIC-73.2%25.7%
ROE-93.2%–

Balance sheet

AAPGABBV
Balance sheet
Cash$171M$10.8B
Total debt–$80.9B
Net debt / EBITDA–3.2
Interest cover–7.1×

Dividends and buybacks

AAPGABBV
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$6.92
Dividend growth a year, past–+6.6%over 5 years
Buyback yield–0.2%
Shareholder yield–2.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AAPG or ABBV

Didn't find what you were looking for?

Ask us
Which is bigger, Ascentage Pharma Group International or AbbVie?

By market value, AbbVie ($506B) is about 453.0 times Ascentage Pharma Group International ($1.1B), at today's prices.

How did AAPG and ABBV stock do over the last 1 years?

Since November 19, 2025, AAPG's price moved -62.8% and ABBV's +22.9%. With dividends: AAPG -62.8% (-62.8% a year), ABBV +26.6% (+26.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, AAPG or ABBV?

The dividend yield at today's price is none for Ascentage Pharma Group International and 2.42% for AbbVie. Over the last twelve months they paid – and $6.92 per share.

Which has the higher profit margins, Ascentage Pharma Group International or AbbVie?

Over the last twelve months, the net margin was -216.5% for Ascentage Pharma Group International and 15.7% for AbbVie, and the operating margin -215.3% and 32.2%. Revenue was $82M and $66.0B.

Which is the better investment, Ascentage Pharma Group International or AbbVie?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.